Kura Oncology is a biopharmaceutical company dedicated to discovering and developing innovative cancer therapies. Through cutting-edge research and a focus on precision medicine, Kura Oncology aims to revolutionize cancer treatment and improve patient outcomes.

Senior Medical Science Liaison - Southeast

Dir/Senior Director, Trade & Patient Access Operations

AD/Director, Marketing Promotions

Associate Director/Director, Biostatistician

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of. At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics. As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality. To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.Reporting to the Vice President of Regulatory Affairs, the Associate Director, Regulatory Operations is a hands-on role responsible for the management and oversight of regulatory submissions, systems, and associated procedures. This role interfaces with external publishing vendor(s) for the preparation of submissions, and internal stakeholders to provide operational oversight and support for eCTD regulatory submission activities. Additionally, the position supports the tracking and archiving of regulatory submissions and health authority correspondence, as well as the management and implementation of regulatory systems and tools. This role is critical to building and continuously improving processes to make regulatory operations best-in-class. Essential Job Functions Direct all regulatory submissions management activities, including submission content and timeline planning and coordination of dossier compilation and QC review to ensure submission quality and compliance for health authority acceptance. Act as submission manager for applications and represent Regulatory Operations on relevant project teams, as needed. Ensure document management tasks are completed in a compliant manner including creation, tracking, storage, and archival of regulatory submissions, correspondence, and other documentation. Manage regulatory records, logs, and databases. Key contact for all enterprise systems related timelines and projects for regulatory information and document management. Serve as business system/process owner, as needed. Oversee the implementation and operation of software and business processes for electronic document and regulatory information management systems (e.g., Veeva RIM), eCTD templates, eCTD publishing tools, and other products as needed (e.g., Veeva PromoMats). Lead the development and implementation of internal procedures, work instructions, and training programs for document and dossier management, archiving, and other processes, as needed. Review and contribute to the creation of standards, templates, and procedures related to regulatory documents, and recommend associated process improvements.&nbsp;Take ownership of building and improving standards, templates, and workflows to create scalable, repeatable processes. Responsible for vendor management, building relationships with business partners and managing budgets and contracts. Provide subject matter expert level strategic insight on regulatory technologies and processes related to registration documents, submission records and associated product data records. Monitor and assess business trends, pending regulations and/or guidance documents for potential regulatory operations impact. Other duties as assigned. Job Requirements BA/BS degree in a science or related field, or equivalent combination of education, experience, and training. 8+ years regulatory operations experience in a biotechnology or pharmaceutical environment with demonstrated ability to present and articulate requirements. Advanced knowledge of regulatory submission requirements, guidelines, and publishing standards, including computer word processing, electronic document management systems, and publishing software. Extensive eCTD filing experience with IND/CTA and NDA stages, including labeling and post-approval promotional materials. Experience managing an outsourced regulatory publishing model is a plus. Experience managing medium to large scale systems (e.g., RIM, EDMS). Experience with Veeva RIM and PromoMats, a plus. Demonstrated ability to facilitate, lead and manage the establishment of procedures. Must be highly detail oriented with the ability to multi-task and shift priorities quickly under tight deadlines with minimal oversight. Drives work independently with ownership and accountability; delivers consistent, high-quality results with minimal oversight. Thrives in a fast-paced, dynamic environment and adapts quickly to shifting priorities. Builds scalable processes and finds better ways of working, always looking to improve efficiency and quality. Strong communicator and collaborator; works effectively across teams and with vendors to keep projects moving. Detail-oriented and organized, with the ability to manage multiple priorities and meet deadlines. #LI-RM1 &nbsp;Kura’s Values that are used for candidate selection and performance assessments: We work as one for patients We are goal-focused and deliver with excellence We are science-driven courageous innovators We strive to bring out the best in each other and ourselves The Kura Package Career advancement/ development opportunities Competitive comp package Bonus 401K + Employer contributions Generous stock options ESPP Plan 20 days of PTO to start 18 Holidays&nbsp; (Including Summer &amp; Winter Break) Generous Benefits Package with a variety of plans available with a substantial employer match Paid Paternity/Maternity Leave In-Office Catered lunches Home Office Setup Lifestyle Spending Stipend Commuter Stipend (Boston Office) Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more! Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of&nbsp;November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at www.kuraoncology.com&nbsp;and follow us on&nbsp;X&nbsp;and&nbsp;LinkedIn. Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.&nbsp; If you are a California resident, please see the attached Privacy Notice CA Privacy Notice

Associate Director, Regulatory Affairs Operations

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of. At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics. As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality. To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.Essential Job Functions The Associate Director/Director of Clinical Pharmacology will be responsible for developing, driving, and implementing nonclinical and clinical ADME strategies. You will be a core member of program teams providing ADME perspectives and delivering modeling and analyses necessary to evaluate nonclinical and clinical options, enable plans, and optimize development programs. This includes gap analysis, study design, PKPD analysis and modeling, program assessment, and collaborations to help execute programs. The successful candidate will bring extensive experience in nonclinical and clinical ADME with the ability to work cross-functionally with multifunctional teams to drive programs to success. Provides clinical pharmacology leadership on multi-disciplinary teams for oncology programs including modeling &amp; simulation to satisfy world-wide regulatory requirements. Provides clinical and nonclinical pharmacokinetic expertise to projects including study design, data analysis and interpretation. Develop population PK, exposure-response, mechanistic PK/PD, PBPK and QSP models, as needed, to evaluate risk/benefit and facilitate drug development decisions. Experience in developing clinical pharmacology and nonclinical strategy and execute studies such as but not limited to drug-drug interaction studies, specific population, BA/BE, and food effect. Provides clinical pharmacology support and leadership in preparation of various regulatory documents including study protocol, CSR, Investigator's Brochure, Clinical Pharmacology section of INDs, CTAs, BLAs and/or NDAs, and clinical pharmacology section of package inserts. Participate in meetings with regulatory agencies and respond to regulatory queries. Job Requirements Ph.D. in Pharmacokinetics, Pharmaceutical Sciences, or a closely related discipline with 5+ years of experience for Associate Director or 8+ years of experience for Director in clinical pharmacology, modeling &amp; simulation, drug metabolism and/or pharmacokinetics within a large pharma and / or biotech companies Experience with nonclinical and clinical pharmacokinetic protocol design with experience working with CRO's is required. Experience in Model Informed Drug Development. Strong organizational and time-management skills including the ability to manage several projects simultaneously. A strong entrepreneurial spirit and a desire to be hands on. Strong analytical and critical thinking skills, and attention to details. Demonstrated creativity in problem solving. Ability to effectively collaborate as part of cross-functional teams and with research partners. Excellent professional interpersonal skills, particularly oral and written communication skills and be able to work in a multidisciplinary team environment. Extensive knowledge of regulatory/guidance requirements (i.e. GLP, FDA, EMA) best practices pharmacokinetic/pharmacodynamic testing and risk assessment based on target indication. The base range for an Associate Director is $172,000- $203,000 and a Director is $228,405 - $260,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.Kura’s Values that are used for candidate selection and performance assessments: We work as one for patients We are goal-focused and deliver with excellence We are science-driven courageous innovators We strive to bring out the best in each other and ourselves The Kura Package Career advancement/ development opportunities Competitive comp package Bonus 401K + Employer contributions Generous stock options ESPP Plan 20 days of PTO to start 18 Holidays&nbsp; (Including Summer &amp; Winter Break) Generous Benefits Package with a variety of plans available with a substantial employer match Paid Paternity/Maternity Leave In-Office Catered lunches Home Office Setup Lifestyle Spending Stipend Commuter Stipend (Boston Office) Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more! Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of&nbsp;November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at www.kuraoncology.com&nbsp;and follow us on&nbsp;X&nbsp;and&nbsp;LinkedIn. Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.&nbsp; If you are a California resident, please see the attached Privacy Notice CA Privacy Notice

Associate Director/Director, Clinical Pharmacology

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of. At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics. As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality. To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.We are seeking an experienced and strategic Associate Director/Director of Pharmacovigilance Operations to lead and evolve our global PV operational infrastructure. This is a high-impact role for someone with strong operational acumen and experience managing outsourced PV models in a biotech or fast-paced pharma environment. This role is accountable for the oversight of all outsourced safety operations, vendor governance, and operational compliance across clinical and post-marketing settings. The Associate Director/Director, PV Operations will play a critical role in scaling PV operations capabilities, ensuring inspection readiness, regulatory compliance, and contributing to strategic safety planning as the company transitions through late-phase development and into commercialization. The ideal candidate has experience supporting both clinical and post-marketing programs and can lead vendor governance, inspection readiness, and PV systems management. This role will support the Pharmacovigilance department and report to the Executive Director of Pharmacovigilance and Drug safety. Key responsibilities of the role include, but not limited to: &nbsp;JOB FUNCTION: Oversee the process for ICSR collection, processing, reconciliation, and reporting, including associated quality activities to ensure regulatory timelines and global standards are met. Provide oversight and support of the PV vendor activities, including establishing and monitoring key performance indicators (KPIs), always ensuring inspection-readiness. Oversee global compliance with pharmacovigilance regulations, including timely ICSR submissions, quality case processing, and aggregate reporting support Oversee the lifecycle of PV operational SOPs, work instructions, and guidance documents, providing oversight to the PV vendor and CROs supporting PV activities. Support in the development and maintenance of Safety Management Plans (SMPs) and Pharmacovigilance Agreements (PVAs), with license partners and/or other parties. Support reconciliation activities between safety and clinical databases, as well as partner case exchanges.&nbsp; Support safety database configuration and maintenance, as required. Support PV audit and inspection activities, as required, and serve as SME during these activities. Oversee deviation and Corrective and Preventive Action (CAPA) activities related to, but not limited to, expedited and periodic reporting activities, as well as deviations related to case management processes, as defined in the SMPs or SOPs. Collaborate with Clinical Operations to deliver safety communications to sites and ethics committees. Assist with PV processes and initiatives, representing PV in collaboration with other functions as needed. Work cross-functionally with Regulatory Affairs, Clinical Operations, Clinical Development, Data Management, Quality Assurance, and Medical Affairs to ensure appropriate PV processes are in place and adhered to. Serves as key point of contact between PV and the CROs regarding PV operation management. Provide PV operational expertise in development of RMPs, REMS, DSURs, PSURs, and other safety deliverables. Represent PV operations in internal safety governance forums and external collaborations/partnerships Participate in cross-functional monitoring of study data, as necessary. Assist in the development, review and management of departmental budget, MSAs, SOWs, invoices and payment of work performed by vendors. Job Requirements Degree in Life Sciences, Pharmacy, Nursing or related field required. Minimum of 10 years of Pharmacovigilance experience within a pharmaceutical, biotechnology or related environment, with time spent in a leadership/managerial role within PV Operations. Hands-on experience in vendor oversight, including governance, ensuring adherence to KPIs, and managing PVAs/SDEAs. Expertise in managing outsourced PV models and developing vendor oversight frameworks. Experience in pre- and post-marketing Safety, with proven success in biotech or small/mid-sized pharma, ideally in a lean team setting. Experience supporting late-stage clinical programs and regulatory submissions (e.g, NDA/BLA/MAA). In-depth knowledge of monitoring health authority submissions, CAPAs and relationships between vendors. Strong understanding of global PV regulatory requirements and timelines (e.g. FDA, EMA, PMDA, E2B R3, etc) and PV Systems (e.g. Argus, Arisglobal, Vault Safety) required. Experience working with clinical databases preferred. Experience with PV aggregate reports, signal detection, safety surveillance, literature review, from a PV operational perspective, is preferred. Able to work independently, establish work priorities, and execute decisions with minimal guidance. Experience in oncology/hematology is preferred. Ability to interpret related regulatory guidance and problem-solve towards a compliance approach with a background and understanding of industry best practices. Excellent strategic, decision-making and analytical skills. Excellent collaboration and strong written and verbal communication skills are required. The base range for an Associate Director is $169,000 - $203,000 and a Director is $218,000 - $255,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus. #LI-RM1Kura’s Values that are used for candidate selection and performance assessments: We work as one for patients We are goal-focused and deliver with excellence We are science-driven courageous innovators We strive to bring out the best in each other and ourselves The Kura Package Career advancement/ development opportunities Competitive comp package Bonus 401K + Employer contributions Generous stock options ESPP Plan 20 days of PTO to start 18 Holidays&nbsp; (Including Summer &amp; Winter Break) Generous Benefits Package with a variety of plans available with a substantial employer match Paid Paternity/Maternity Leave In-Office Catered lunches Home Office Setup Lifestyle Spending Stipend Commuter Stipend (Boston Office) Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more! Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of&nbsp;November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at www.kuraoncology.com&nbsp;and follow us on&nbsp;X&nbsp;and&nbsp;LinkedIn. Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.&nbsp; If you are a California resident, please see the attached Privacy Notice CA Privacy Notice

Associate Director/Director, Drug Safety Operations

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of. At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics. As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality. To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.ESSENTIAL JOB FUNCTIONS: The Director of Commercial Analytics and Performance Reporting will play an integral role in the successful launch of Kura Oncology’s lead program. &nbsp;This role will lead our Commercial Analytics activities, leveraging data to drive robust analytical insights that inform our most critical business questions. S/he will work with cross-functional partners to identify and prioritize business questions, develop appropriate analytical approaches and frameworks, and generate insights to maximize commercial opportunities. This role is dynamic, fast-paced, highly collaborative, and will require a demonstrated ability to communicate intricate data concepts and drive action among a diverse group of stakeholders through compelling presentations and dashboards. Key Responsibilities: Development and implementation of best-in-class strategies to align advanced analytics and data science initiatives with overall business goals Act as strategic partner to frame, investigate, and answer key business questions related to performance reporting, including executive reporting and interactions with senior commercial leaders. Develop and execute creation of in-house insights-ready reports and dashboards to drive actionable insights from internal and secondary data sources. Lead the evaluation, tracking, and reporting of brand performance metrics and KPIs through compelling weekly, monthly and quarterly presentations with brand and leadership teams Connect insights together to tell a compelling and persuasive story and deliver clear and actionable recommendations. Partner with colleagues to advance the use of data sources and reporting, including I&amp;A, Sales &amp; Marketing, Agency partners, Market access, RWD, etc. Be accountable for continuous improvement and identification/utilization of new capabilities to maximize the competitive advantages of the business Hands-on ability to leverage diverse datasets to identify insights that inform marketing and sales strategies, shape the customer experience, and elevate impact of omnichannel programs. Oversee data quality management process for assigned brand/s with external and internal data providers to ensure timely, accurate and complete patient and specialty pharmacy data. Act as a key “go-to person” for resolving field reporting and data inquiries issues. Expertise in leading vendors/offshore data partners on connecting, integrating, and synthesizing analysis into a meaningful ‘so what’ recommendation Proven ability to act as a strategic partner with the capacity to quickly establish relationships of trust, credibility, and be seen as a partner Ability to identify, prioritize and describe relevant caveats and uncertainties in data, including how they relate to the business question and broader strategic priorities. Provide thought partnership in building and standardizing commercial reporting. JOB SPECIFICATIONS: Bachelor’s Degree (BS/BA) in an analytic discipline - engineering, mathematics, statistics, economics, etc. Master’s degree in a similar field or an MBA preferred. 10+ years of progressive leadership experience in analytics. Strong analytical, coding skills (such as: Python, R, SQL, etc.), MS Excel and PowerPoint skills. Strong knowledge of internal sales data (i.e. SP, field execution, promotional metrics) and third party pharmaceutical sales and script data (DDD, NSP, Xponent, DataView, longitudinal patient data, claims data, etc.) Advanced knowledge and experience developing BI tools for commercial pharma applications (Power BI, Tableau, Qlik, MicroStrategy, etc.) Expertise in data analysis and in building successful strategies using advanced data driven analysis and reporting (next-best action etc) that drive business results. Strong leader with the ability to persuade and influence others, and develop/deliver impactful presentations Excellent organizational skills and the ability to balance multiple demands Excellent communication, presentation and interpersonal skills Proven and successful team player Must be able to meet deadlines, stay organized, and be self-sufficient The base range for a Director is $226,000 - $260,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus. #LI-RM1Kura’s Values that are used for candidate selection and performance assessments: We work as one for patients We are goal-focused and deliver with excellence We are science-driven courageous innovators We strive to bring out the best in each other and ourselves The Kura Package Career advancement/ development opportunities Competitive comp package Bonus 401K + Employer contributions Generous stock options ESPP Plan 20 days of PTO to start 18 Holidays&nbsp; (Including Summer &amp; Winter Break) Generous Benefits Package with a variety of plans available with a substantial employer match Paid Paternity/Maternity Leave In-Office Catered lunches Home Office Setup Lifestyle Spending Stipend Commuter Stipend (Boston Office) Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more! Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of&nbsp;November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at www.kuraoncology.com&nbsp;and follow us on&nbsp;X&nbsp;and&nbsp;LinkedIn. Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.&nbsp; If you are a California resident, please see the attached Privacy Notice CA Privacy Notice

Director, Commercial Analytics and Performance Reporting

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of. At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics. As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality. To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.We’re looking for a Director/Senior Director, Clinical Development (MD) to lead cross-functional clinical teams for the design and conduct of clinical studies.&nbsp; ESSENTIAL JOB FUNCTIONS: Lead cross-functional clinical teams for the design and conduct of oncology studies. Ensure that scientific rigor and innovation drives Kura Oncology’s development strategies. Ensure excellence in both strategy and execution by partnering closely with colleagues in clinical operations, biostatistics, data management, program management and translational medicine. Serve as Medical Monitor of sponsored clinical research and as medical representative to CROs, reference laboratories and other organizations involved in the execution of clinical trials. Responsible for of all clinical regulatory deliverables and other clinical documents associated with the clinical trials under his/her direct responsibility, including protocols, and the clinical portion of INDs, CTAs, investigator brochures, CRF’s, annual IND reports, CSR’s and clinical expert reports, among others. Responsible for the analysis of clinical data, including safety monitoring in collaboration with PV. Participate in site initiation visits and other site visits at clinical center. JOB SPECIFICATIONS: Minimum of 3 years of relevant experience in drug development either in industry (preferred) or in academia. M.D. degree required. Proven track record of strong clinical research skills, including publications. Ability to partner with others to implement innovative development strategies. Experience in precision oncology/hematology. Demonstrated excellence in independently leading and conducting research and ability to evaluate, interpret and present complex scientific data. Demonstrated written and excellent communication and interpersonal skills, with the ability to translate statistical concepts into layman's terms. Strong attention to detail with ability to understand the broader picture and priorities. Must be a dedicated self-starter with a high energy level and ability to achieve results. Must have strong communication and leadership skills-the ability to influence and work successfully with colleagues, customers, and corporate partners. The candidate should have experience in handling multiple projects at a time. Some travel may be required when appropriate. The base range for this role at the Director level is 281,000 - $323,000 and Senior Director level is $341,000 to $387,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus. #LI-RM1Kura’s Values that are used for candidate selection and performance assessments: We work as one for patients We are goal-focused and deliver with excellence We are science-driven courageous innovators We strive to bring out the best in each other and ourselves The Kura Package Career advancement/ development opportunities Competitive comp package Bonus 401K + Employer contributions Generous stock options ESPP Plan 20 days of PTO to start 18 Holidays&nbsp; (Including Summer &amp; Winter Break) Generous Benefits Package with a variety of plans available with a substantial employer match Paid Paternity/Maternity Leave In-Office Catered lunches Home Office Setup Lifestyle Spending Stipend Commuter Stipend (Boston Office) Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more! Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of&nbsp;November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at www.kuraoncology.com&nbsp;and follow us on&nbsp;X&nbsp;and&nbsp;LinkedIn. Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.&nbsp; If you are a California resident, please see the attached Privacy Notice CA Privacy Notice

Director/Senior Director, Clinical Development -Hematology/Oncology

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of. At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics. As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality. To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.Key responsibilities include oversight of outsourced data management &amp; EDC activities by service providers, performing and coordinating internal study team data review, and delivery of fit for purpose clinical data in support of study milestones. ESSENTIAL JOB FUNCTIONS: Provide clear, consistent communication to Kura’s CROs and 3rd party Vendors with respect to data management deliverables and monitor performance against communicated expectations. Coordinate internal team review and feedback during EDC builds and/or migrations and provide clear guidance to external DM and EDC build team throughout. Accountable for DM task and milestone timelines Responsible for ensuring data quality and integrity for clinical study data collection activities. Work with clinical team to define and maintain the Kura Comprehensive Data Review Plan. Lead Kura study team in the review of clinical study data per Comprehensive Data Review Plan. Prepare and provide internal data listings and reports as required. Review protocols for data collection and management feasibility. Provide leadership to the study team with respect to data management activities throughout the study lifecycle: planning, start-up, conduct, close-out. Accountable for the creation and delivery of DM documentation (i.e., eCRFs, CCGs, DMP, Data Transfer Specifications, etc.); ensure documentation is appropriately filed within the Trial Management File (TMF). Review study budgets and provide input on data collection, cleaning, and reporting as it relates to development of vendor contracts Partner with internal content experts to manage and coordinate data collection/maintenance with external vendors; ensure deliverables are identified and met according to project milestones and program/project objectives. Responsible for tracking and documenting data management decisions. Responsible for initiating and chairing meetings associated with assigned studies and initiatives Provide support and contribute to the development of clinical trial timelines as it relates to data management activities. Manage accruals tracking and vendor payments for data management activities. Contribute to the development of departmental procedures documentation. Complete other duties as assigned by the JOB SPECIFICATIONS: A./B.S. degree in Biology, Mathematics, Computer Science or related scientific field. 5+ years’ experience in data management or relevant work in the pharmaceutical/biopharma industry. Experience in oncology strongly preferred. Experience in managing DM activities throughout the study lifecycle (planning, start-up, conduct, close-out) Significant experience providing oversight for database migrations. Experience with an NDA submission desirable Strong project management skills Strong vendor management skills (e.g. Biomarkers, Labs, Imaging, ECG). Able to provide independent DM subject matter expertise to study teams and vendors in defining, managing, &amp; delivering on DM obligations. Experience working in 1 or more EDC platforms (Rave, InForm, etc.). Experience working in a data integration/visualization platform (e.g. Saama, elluminate) desirable Solid understanding of clinical drug development process and knowledge of regulatory requirements and ICH/GCP guidelines. Excellent planning, organization and time management skills including the ability to support and prioritize multiple projects. Excellent interpersonal skills in addition to verbal and written communication skills. Strong Excel skills, SAS experience a plus Flexibility to travel up to approximately 5% of &nbsp; The base range for a Manager is $150,000 - $180,000 and for a Senior Manager it's $178,000 - $213,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus. #LI-RM1Kura’s Values that are used for candidate selection and performance assessments: We work as one for patients We are goal-focused and deliver with excellence We are science-driven courageous innovators We strive to bring out the best in each other and ourselves The Kura Package Career advancement/ development opportunities Competitive comp package Bonus 401K + Employer contributions Generous stock options ESPP Plan 20 days of PTO to start 18 Holidays&nbsp; (Including Summer &amp; Winter Break) Generous Benefits Package with a variety of plans available with a substantial employer match Paid Paternity/Maternity Leave In-Office Catered lunches Home Office Setup Lifestyle Spending Stipend Commuter Stipend (Boston Office) Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more! Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of&nbsp;November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at www.kuraoncology.com&nbsp;and follow us on&nbsp;X&nbsp;and&nbsp;LinkedIn. Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.&nbsp; If you are a California resident, please see the attached Privacy Notice CA Privacy Notice

Manager/Senior Manager, Clinical Data Sciences

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of. At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics. As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality. To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.ESSENTIAL JOB FUNCTIONS: Partner with the SVP of IR and Corp Affairs as well as the Senior Director, Corporate Communications to develop and execute Kura’s communications strategies and tactics to amplify our story and advance our reputation Support product communications in collaboration with clinical and commercial teams Partners with Commercial to manage and execute the company’s social media strategies and enhance patient advocacy relationships Partners with Human Resources to assist with internal communications, drive employee engagement and further strengthen corporate culture Support internal communications by drafting articles for the Company intranet and supporting the periodic newsletter distribution Manage corporate social media content and calendar across LinkedIn, X (Twitter), YouTube, and other platforms; track performance analytics Coordinates and maintains a communications calendar Support preparation of investor relations materials, including press releases, conference call scripts and presentations Analyze industry/market trends and perform competitor analysis. Communicate relevant insights to the IR team and leadership Coordinate logistics for investor conferences and events. Manage updates to corporate website to ensure compliance with public disclosure, positioning, key corporate messages, and regulatory requirements Supports community relations and corporate giving efforts and other CSR activities on behalf of the company; creates materials and content to showcase our community efforts externally Coordinates and supports leadership team with media interviews, speaking engagements and participation in investor events Oversee the use of corporate brand standards and style guidelines to ensure quality and uniformity across all communications channels Ensures high quality and timely results for all communications Other duties as requested by supervisor &nbsp; JOB SPECIFICATIONS: Accredited Bachelor’s degree preferably in Communications, English, Journalism or related field Prior experience in biopharmaceutical industry in a corporate or agency role strongly preferred 5+ years of relevant experience in corporate communications or related field Ability to demonstrate strong presence and cultivate relationships with senior leadership team Outstanding interpersonal and communication skills, both written and verbal Interest/knowledge in graphic design and the interplay between user interfaces and experience, copywriting and content strategy Self-starter, able to work well as a member of a team, but also work independently with limited oversight Track record of managing issues and ability to stay calm under pressure Strong project management skills and a history of driving projects to completion in a fast-paced environment General working knowledge of essential computer applications (i.e. MS Word, Excel, PowerPoint, CRM) Ability to influence others Ability to multi-task The base range for a Manager is $145,000 - $168,000 and a Senior Manager is $175,000 - $220,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus. #LI-RM1Kura’s Values that are used for candidate selection and performance assessments: We work as one for patients We are goal-focused and deliver with excellence We are science-driven courageous innovators We strive to bring out the best in each other and ourselves The Kura Package Career advancement/ development opportunities Competitive comp package Bonus 401K + Employer contributions Generous stock options ESPP Plan 20 days of PTO to start 18 Holidays&nbsp; (Including Summer &amp; Winter Break) Generous Benefits Package with a variety of plans available with a substantial employer match Paid Paternity/Maternity Leave In-Office Catered lunches Home Office Setup Lifestyle Spending Stipend Commuter Stipend (Boston Office) Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more! Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of&nbsp;November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at www.kuraoncology.com&nbsp;and follow us on&nbsp;X&nbsp;and&nbsp;LinkedIn. Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.&nbsp; If you are a California resident, please see the attached Privacy Notice CA Privacy Notice

Manager/Sr. Manager, IR & Corporate Communications

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of. At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics. As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality. To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.ESSENTIAL JOB FUNCTIONS: General: Responsible for the planning and management of the operational aspects of clinical trials, including CRO and vendor management/oversight, ensuring project milestones and objectives are met and clinical study deliverables are consistent with program/company goals. Collaborate with internal and external team members for the planning and execution of clinical trials. Accountable for coordination of planning, initiation, completion, and reporting of clinical study protocols within or across programs from team endorsement to reporting. Ensure clinical trials meet time, quality, and cost targets consistent with the overall Clinical Development Plan. Lead the development of and provide input into study-related documents, including ICFs, CRFs, monitoring plans, study, lab and pharmacy manuals, data management plans, etc. Also performs review and provides strong operational input in the development of clinical trial protocols and CSRs Contribute to department documentation development, such as the development and writing of Standard Operating Procedures (SOPs). Collaborate with Legal &amp; Clinical Contracting &amp; Outsourcing (and others, as needed) on the development and management of study specific agreements/budgets (i.e., non-disclosure agreements, clinical trial agreements, clinical research organization agreements, etc.). Organize and manage project timelines and budgets; help ensure project deliverables are on time and within budget and amended accordingly. Provides leadership and contributes to all operational aspects of the trial budget, including forecasts to ensure delivery within the business financial standards. Oversee the conduct of studies and ensure studies are implemented according to the study protocols and in compliance with local, ICH, GCP and company policies and procedures. Monitor and visit clinical study sites as needed. Track, collect, and review clinical documentation for clinical trials. Complete other duties as assigned by the manager. Key contributor to the development of annual trial/project objectives and communicating to relevant line management and Clinical Strategy Team (CST). Serves as the key CST point of contact for the trial. Accountable for the successful preparation and presentation of operational content at key leadership discussions (CST, GPT, SLT, etc.). Ensures strong oversight, review, and delivery of trial/project CAPAs in order to meet corporate compliance standards and timelines. Accountable for partnering with CRO in audit responses and addressing quality issues. Filters, prioritizes, analyzes, and validates complex and dynamic information from a diverse range of external and internal sources to respond to technical operational and organizational challenges. Ensures inspection readiness application for all assigned clinical trials. Sr. CTL: Manages projects/work streams with high complexity, risk, impact, and reach. Manages large-sized global clinical teams with members also from outside the direct working environment.&nbsp; Coordinates stakeholders from closely related areas and beyond. Demonstrates skills in successfully leading international teams in the matrix organization and directs, influences, and motivates people; creates and leads a positive working climate.&nbsp; Develop and lead operational and therapeutic area training for internal and external study team members. Directs multiple studies in parallel and/or be called upon for program management duties. Exhibits Subject Matter Expert level understanding of multiple functions and functional processes. Accountable for successful project execution including definition of milestones and clarification of project scope.&nbsp; Receives minimal guidance and works independently.&nbsp; Acts as a senior advisor and mentor within the team and beyond and serves as best practice resource within own discipline or as technical expert on cross functional teams or projects JOB SPECIFICATIONS: Advanced degree desirable; PM certification desirable Ideally 10 years clinical research experience with at least 5 years of direct trial management experience Some experience in oncology preferred. Experience in CRO oversight is required Manages large sized global clinical trial team Works with minimal or no supervision Ability to mentor junior staff Self-directed and proactive handles multiple complex tasks Strong organization, documentation, and communication skills. Excellent interpersonal skills: ability to collaborate across disciplines. Detailed knowledge of GCP, ICH Guidelines and current US FDA regulations. Ability to travel up to approximately 30% of time. Hybrid on-site in Boston two days per week. #LI-RM1Kura’s Values that are used for candidate selection and performance assessments: We work as one for patients We are goal-focused and deliver with excellence We are science-driven courageous innovators We strive to bring out the best in each other and ourselves The Kura Package Career advancement/ development opportunities Competitive comp package Bonus 401K + Employer contributions Generous stock options ESPP Plan 20 days of PTO to start 18 Holidays&nbsp; (Including Summer &amp; Winter Break) Generous Benefits Package with a variety of plans available with a substantial employer match Paid Paternity/Maternity Leave In-Office Catered lunches Home Office Setup Lifestyle Spending Stipend Commuter Stipend (Boston Office) Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more! Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of&nbsp;November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at www.kuraoncology.com&nbsp;and follow us on&nbsp;X&nbsp;and&nbsp;LinkedIn. Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.&nbsp; If you are a California resident, please see the attached Privacy Notice CA Privacy Notice

Senior Clinical Trial Leader

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of. At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics. As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality. To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.ESSENTIAL JOB FUNCTIONS: The Senior Director, Corporate Communications, is a dynamic, experienced leader who, as a critical member of the investor relations and corporate affairs team, will shape our narrative, elevate our brand and build trust across key audiences, with a strong focus on external, product and pipeline communications to support our company’s growth. The successful candidate will develop and implement a comprehensive corporate communications strategy that aligns with the company’s vision, values, and business goals. H/She will ensure information complies with all guidelines and SEC regulations. The ideal candidate will have experience in the biotechnology and/or pharmaceutical industry developing communications campaigns and managing creative brand awareness programs across multiple channels and audiences. This role will report to the Senior Vice President of Investor Relations and Corporate Affairs and have regular interactions with the executive team including the Chief Executive Officer, Chief Medical Officer, Chief Commercial Officer and other key members of the management team. Responsibilities Manage the development and execution of strategic communications plans and initiatives aligned with our corporate goals to build company awareness with key stakeholders and support the business Collaborate regularly with other functions within the company and outside agencies to elevate key corporate milestones, create compelling storylines to drive media coverage and increase brand awareness Create a comprehensive digital media plan incorporating various platforms (social, web, video), developing creative content and design, ensuring messaging consistency and measuring success; manage Kura Oncology’s social media accounts Draft communications materials, including news releases, Q&amp;A documents, talking points, interview briefs, corporate presentations, social media, website copy and other digital content Design and implement a comprehensive executive thought leadership strategy Collaborate with multiple functions on pipeline milestones and data readouts, develop and manage effective crisis communications Serve as a liaison between the external partner communications team, Finance, Marketing, Commercial, Clinical Development, and BD teams. Coordinate the creation of a unified communication calendar to align efforts, key dates, and messages across departments. JOB SPECIFICATIONS: Bachelor’s or advanced graduate degree a related discipline. 10 + years in the biotech/pharmaceutical industry or public relations agency. Direct experience leading Corporate Communications at a public biopharma company or agency. Strong writing skills in a variety of areas, from scientific information to creative writing. Ability to distill scientific information into clear and concise corporate messaging and materials, including press releases and Q&amp;A. Experience in driving results in media relations, digital and social media, and pipeline/product communications. Recognized as an expert and trusted advisor with a proven track record in crafting, executing, and steering top-tier corporate communication strategies and initiatives that yield tangible, measurable outcomes. Excellent interpersonal skills to facilitate interactions with all levels of the organization and manage and lead projects involving cross-functional teams. Strong collaborator that knows how to drive projects forward, meets or exceeds deadlines and can work in a fast-paced environment. Ability to present and express ideas and information clearly and confidently in a manner appropriate to the specified audience, whether verbal or written. Ability to travel periodically as required. The base range for a Senior Director is $265,000 - $300,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus. #LI-RM1Kura’s Values that are used for candidate selection and performance assessments: We work as one for patients We are goal-focused and deliver with excellence We are science-driven courageous innovators We strive to bring out the best in each other and ourselves The Kura Package Career advancement/ development opportunities Competitive comp package Bonus 401K + Employer contributions Generous stock options ESPP Plan 20 days of PTO to start 18 Holidays&nbsp; (Including Summer &amp; Winter Break) Generous Benefits Package with a variety of plans available with a substantial employer match Paid Paternity/Maternity Leave In-Office Catered lunches Home Office Setup Lifestyle Spending Stipend Commuter Stipend (Boston Office) Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more! Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of&nbsp;November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at www.kuraoncology.com&nbsp;and follow us on&nbsp;X&nbsp;and&nbsp;LinkedIn. Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.&nbsp; If you are a California resident, please see the attached Privacy Notice CA Privacy Notice

Senior Director, Corporate Communications

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of. At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics. As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality. To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.ESSENTIAL JOB FUNCTION: Act as the “CEO” for Kura’s lead menin inhibitor, ziftomenib, fostering a sense of mission, creativity and urgency. Lead the Global Program Team: an empowered multi-disciplinary team of leaders Develop near and long-term strategic objectives and recommendations for the asset across all indications from early to late-stage development and ongoing lifecycle management Accountable - the single point of accountability for all Global Program Team activities Define and lead the membership of the core and extended team Focus on full cross-functional business including clinical development, commercial, CMC, finance, and business development Extended partnership with global program management, commercial and development functional leads, external partners, and Senior Leadership Team Work with the team and with senior leaders to define the strategic direction for the asset and plays a key role, driving execution of asset goals, and ensuring alignment and integration among Core Global Program Team and Extended Teams. Form a close partnership with department leads and with program management to build program plans, identify and mitigate risks, capitalize on asset opportunities, manage budgets, and timelines and ensure best practices. Represent the program to internal and external stakeholders, including collaboration partners and the Board of Directors. Lead key program team meetings and serve as a point of escalation for the program to senior leadership. Help build best practices for efficient and effective program teams. Support external stakeholders engagement including Health Authorities, potential strategic partners, vendors and and KOLs. Drive cross-functional collaboration and act as the owner of the Asset Integrated Development Plan Work with corporate affairs on investor communications to optimize external program communications Partner directly with the SVP, Global Program Leadership to lead change and evolution of program and portfolio strategy to enhance decision-making, build high-performing teams, and optimize portfolio decisions across programs &nbsp; JOB SPECIFICATIONS: 15+ years drug development and commercialization experience 10+ years oncology experience, with preference in heme/oncology Prior experience with partnered programs (development and/or commercial) will be valuable Highly visible role focused on cross-functional team leadership, including strategy development, communication and driving tactical delivery of programs Strategy, Project, Program and Portfolio Management, Talent Development, Mentorship and Alliance Management expertise Advanced Degree (MBA, MS, PharmD, PhD) Build trust, transparency, and clear communication plans Connect strategic vision for asset strategy to the competitive environment and company strategy Ability to understand and communicate complex scientific and commercial matters while keeping the big picture in mind and the credibility to engage subject matter experts on details at all levels in the organization Ability to consider and integrate different points of view, new ideas etc.; demonstrates self-awareness and emotional intelligence Thorough understanding of company specific matrix organization, functional impact and regional representation to proactively build the relationships needed to be successful across functions and departments The base range for a Vice President is $333,000 - $368,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus. #LI-RM1Kura’s Values that are used for candidate selection and performance assessments: We work as one for patients We are goal-focused and deliver with excellence We are science-driven courageous innovators We strive to bring out the best in each other and ourselves The Kura Package Career advancement/ development opportunities Competitive comp package Bonus 401K + Employer contributions Generous stock options ESPP Plan 20 days of PTO to start 18 Holidays&nbsp; (Including Summer &amp; Winter Break) Generous Benefits Package with a variety of plans available with a substantial employer match Paid Paternity/Maternity Leave In-Office Catered lunches Home Office Setup Lifestyle Spending Stipend Commuter Stipend (Boston Office) Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more! Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of&nbsp;November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at www.kuraoncology.com&nbsp;and follow us on&nbsp;X&nbsp;and&nbsp;LinkedIn. Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.&nbsp; If you are a California resident, please see the attached Privacy Notice CA Privacy Notice

Get a job referral to Kura Oncology

Your career is worth investing in.

Get unlimited referrals with Premium.